HomeCompareESYL vs JNJ

ESYL vs JNJ: Dividend Comparison 2026

ESYL yields 28409.09% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ESYL wins by $1.717285579085763e+21M in total portfolio value
10 years
ESYL
ESYL
● Live price
28409.09%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.717285579085763e+21M
Annual income
$1,705,476,225,933,961,000,000,000,000.00
Full ESYL calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ESYL vs JNJ

📍 ESYL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodESYLJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ESYL + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ESYL pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ESYL
Annual income on $10K today (after 15% tax)
$2,414,772.73/yr
After 10yr DRIP, annual income (after tax)
$1,449,654,792,043,867,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, ESYL beats the other by $1,449,654,792,043,867,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ESYL + JNJ for your $10,000?

ESYL: 50%JNJ: 50%
100% JNJ50/50100% ESYL
Portfolio after 10yr
$858642789542881525760.00M
Annual income
$852,738,112,966,980,500,000,000,000.00/yr
Blended yield
99.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ESYL
No analyst data
Altman Z
-26.2
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ESYL buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricESYLJNJ
Forward yield28409.09%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$1.717285579085763e+21M$30.3K
Annual income after 10y$1,705,476,225,933,961,000,000,000,000.00$4,689.40
Total dividends collected$1.7165083358604254e+21M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ESYL vs JNJ ($10,000, DRIP)

YearESYL PortfolioESYL Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$2,851,609$2,840,909.09$10,592$272.30+$2.84MESYL
2$760,169,183$757,117,961.69$11,289$357.73+$760.16MESYL
3$189,438,723,309$188,625,342,283.08$12,123$472.89+$189438.71MESYL
4$44,134,070,922,101$43,931,371,488,160.32$13,141$629.86+$44134070.91MESYL
5$9,612,471,011,181,248$9,565,247,555,294,598.00$14,408$846.81+$9612471011.17MESYL
6$1,957,319,145,589,813,500$1,947,033,801,607,849,500.00$16,021$1,151.60+$1957319145589.80MESYL
7$372,618,306,540,028,800,000$370,523,975,054,247,700,000.00$18,122$1,588.22+$372618306540028.81MESYL
8$66,321,415,854,837,685,000,000$65,922,714,266,839,850,000,000.00$20,930$2,228.20+$66321415854837688.00MESYL
9$11,036,778,646,544,110,000,000,000$10,965,814,731,579,433,000,000,000.00$24,792$3,191.91+$11036778646544109568.00MESYL
10$1,717,285,579,085,763,000,000,000,000$1,705,476,225,933,961,000,000,000,000.00$30,274$4,689.40+$1.717285579085763e+21MESYL

ESYL vs JNJ: Complete Analysis 2026

ESYLStock

Easylink Solutions Corp., a development stage company, provides IT related management and services to small to medium sized corporate entities in Hong Kong. The company collects, manages, and transmits uninterrupted digital information, as well as manufactures hard drives and solid state drives, including external and portable storage devices. Its products include home digital media center that enables the user to play various digital media to television screen, as well as plays various picture and audio formats. Easylink Solutions Corp. sells its products through a networked group of independent and company-owned dealers, as well as retail and Web-based channels. The company was formerly known as AlgoDyne Ethanol Energy Corp. and changed its name to Easylink Solutions Corp. in November 2008. Easylink Solutions Corp. was incorporated in 2004 and is based in Haifa, Israel.

Full ESYL Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ESYL vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ESYL vs SCHDESYL vs JEPIESYL vs OESYL vs KOESYL vs MAINESYL vs ABBVESYL vs MRKESYL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.